DMA4-H228
Version 1.47414e6a · 2026-09-13
| CAS No. | Not available |
| Chemical Name | DMA4-H228 |
| Synonyms | DMA4H228， DMA4 H228， |
| SMILES | CCCCCCCCN(CCCCCCCC)C(=O)CCC(=O)OCCOC(=O)CCN(CCC(=O)OCCOC(=O)CCC(=O)N(CCCCCCCC)CCCCCCCC)CCC1CCCN1C |
| Formula | C57H106N4O10 |
| M.Wt | 1,007.49 |
| Purity | ELSD-HPLC>95% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Dimethylamino-based synthetic lipidoid nanoparticles for selective mRNA delivery to splenic antigen-presenting cells-Journal of Controlled Release Volume 382, 10 June 2025, 113737 |
DMA4-H228 is a novel, biodegradable lipidoid specifically engineered for spleen-targeted mRNA delivery. Its structure combines a dimethylamino (DMA4) headgroup with a unique hyperbranched lipid tail (H228) synthesized via Michael addition, incorporating ester bonds for enhanced biodegradability. This design enables the formation of stable lipid nanoparticles (LNPs) (~170 nm) with high mRNA encapsulation efficiency (>96%). Critically, DMA4-H228 exhibits exceptional intrinsic tropism for the spleen (>98% targeting efficiency after IV administration), requiring no external targeting ligands. It selectively delivers mRNA to splenic antigen-presenting cells (APCs), including dendritic cells, macrophages, and B cells. This triggers potent immune activation: rapid IFNα secretion, upregulation of APC maturation markers (CD86/CD40), and robust antigen-specific immune responses. Demonstrating significant therapeutic potential, DMA4-H228-based mRNA vaccines effectively inhibit tumor growth in melanoma models (e.g., B16F10-OVA). This correlates with increased tumor-infiltrating CD8⁺ T cells, a shift towards pro-inflammatory M1 macrophages, elevated antigen-specific antibodies (IgG), and strong T cell responses (evidenced by IFNγ⁺ spots). Its ability to bypass liver tropism and directly activate splenic APCs makes DMA4-H228 a powerful platform for next-generation mRNA vaccines and cancer immunotherapy.
Specifications shown are product-page values, not batch test results.
Read Instructions for Use →